Clinical trials: Eczema
Atopic Dermatitis
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with…
- Trial name
- NCT03738423
- Testing
- REGN3500
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 129 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Exploratory Study on Lactibiane Topic AD on Skin Flora and Barrier Reinforcement in Mild to Moderate Atopic Dermatitis
This exploratory study aims to evaluate the impact of a cosmetic product (Lactibiane Topic AD) vs placebo on skin flora and skin reinforcement barrier in mild to moderate atopic dermatitis using biometrological, biological and…
- Trial name
- NCT04728269
- Testing
- Lactibiane Topic AD
- Where
- France
- Volunteers
- 10 people
- Sponsor
- PiLeJe
Healthy Subjects and Atopic Dermatitis Subjects
A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis
The purpose of the study is to determine safety and tolerability of IL-31 mAB
- Trial name
- NCT01614756
- Testing
- BMS-981164
- Where
- 4 sites in United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Atopic Dermatitis
Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis
- Trial name
- NCT05186805
- Testing
- Tapinarof cream, 1%
- Where
- 10 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.
- Trial name
- NCT05048056
- Testing
- AK120
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Akesobio Australia Pty Ltd
Atopic Dermatitis
A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis
To observe the safety and effectiveness of long-term use of jaktinib hydrochloride tablets in the treatment of moderate and severe atopic dermatitis
- Trial name
- NCT05676242
- Testing
- Jaktinib Hydrochloride Tablet
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Dermatitis, Atopic
Treatment of Atopic Dermatitis by a Full-Body Blue Light Device
Multicentric, placebo-controlled, double-blinded, three-armed, prospective, randomized controlled trial.150 patients diagnosed with atopic dermatitis will be randomized to arm 1 (irradiation for 30min at 415nm wavelength), arm 2…
- Trial name
- AD-Blue (NCT03085303)
- Testing
- Full Body Blue Light Device
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 87 people
- Sponsor
- Philips Electronics Nederland BV
Dermatitis Atopic
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
Primary Objective: Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in predefined lesional skin in pediatric participants with moderate to severe atopic…
- Trial name
- PELISTAD (NCT04718870)
- Testing
- Dupilumab SAR231893
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dermatitis, Atopic
Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis
The study shall explore whether treatment of atopic dermatitis is equally effective with respect to a marketed medical device and a new medical device.
- Trial name
- Phoenix II (NCT01948869)
- Testing
- Phoenix II (BAY81-2996), Phoenix I (BAY81-2996)
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Bayer
Atopic Dermatitis, Psoriasis
Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.
- Conditions
- Atopic Dermatitis, Psoriasis, Asthma
- Trial name
- NCT04927195
- Testing
- EDP1867
- Where
- 7 sites in United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Atopic Dermatitis
Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product…
- Trial name
- NCT02896101
- Testing
- Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream
- Where
- 27 sites in United States
- Volunteers
- 755 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Atopic Dermatitis
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
The purpose of this study is to see how a medicine called PF-08049820 affects how other medicines move through the body. This information will help plan future studies.
- Trial name
- NCT07190430
- Testing
- PF-08049820, Midazolam, Dabigatran Etexilate
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Mild to Moderate Atopic Dermatitis
A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis
To show therapeutic efficacy of Zarzenda cream compared to Elidel cream in children and adolescents with mild to moderate atopic dermatitis
- Trial name
- NCT00568412
- Testing
- Zarzenda, Elidel
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Bayer
Atopic Dermatitis
Effectiveness of a Combined Dermatological Treatment in Children With Atopic Dermatitis
The purpose of this study is to determine the effectiveness of a combined dermatological treatment in children up to 5 years old with mild or moderated atopic dermatitis.
- Trial name
- KAOS (NCT02920411)
- Testing
- Pediatopic Treatment Cream, Pediatopic Body lotion
- Where
- 2 sites in Spain
- Volunteers
- 43 people
- Sponsor
- Laboratorios Ordesa
Atopic Dermatitis
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy.
- Trial name
- ADsolve (NCT07006792)
- Testing
- Lebrikizumab
- Where
- 66 sites in United States, Argentina and 3 more
- Volunteers
- 233 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
- Trial name
- NCT06055361
- Testing
- BxC-I17e (primed iMSC derived Extracellular vesicles(EV))
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Brexogen Inc.
Skin Diseases
A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis
This is an open-label, randomized, comparative study, including 4 phases: SCREENING, ACUTE, MAINTENANCE and FOLLOW-UP. Subjects will complete the SCREENING phase to check the eligibility within 7 days after they sign the written…
- Trial name
- NCT01915914
- Testing
- Fluticasone propionate
- Where
- 4 sites in China
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Dermatitis, Atopic
Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106)
Long-Term Follow-up Study of Subjects With Moderate to Severe Chronic Atopic Dermatitis Who Had Administered FURESTEM-AD Inj. in K0106 Study
- Trial name
- NCT07582237
- Where
- South Korea
- Volunteers
- 262 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis (AD)
PRA-216 Atopic Dermatitis Safety and Efficacy Study
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
- Trial name
- NCT07810777
- Testing
- Active PRA-216
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 39 people
- Sponsor
- Prana Therapies Inc
Eczema, Hand Eczema
A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema
The primary objective of this protocol is to acquire pilot data for a larger study to test the following hypothesis: Treatment of the hands of patients with chronic hand dermatitis/atopic dermatitis with CLn BodyWash, a novel gel…
- Conditions
- Eczema, Hand Eczema, Atopic Dermatitis
- Trial name
- NCT01826630
- Testing
- CLn BodyWash, Cetaphil Daily Facial Cleanser
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shari L Hand
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.